Alzheimer’s disease (AD) is progressive, but slow to develop — or at least to reveal itself. In a new study, published online February 14, 2020 in the journal Biological Psychiatry, researchers at University of California San Diego School of Medicine, with colleagues elsewhere, report that early, subtle differences in cognitive performance, such as fewer words recalled on a memory test, are a sign that harmful proteins are accumulating in the brain, even if levels of those proteins do not yet qualify as dangerous.
Pathologically, AD is primarily characterized by the accumulation of protein plaques called β-amyloid (Aβ), which gradually accumulate in the brain, disrupting cell function and eventually killing affected neurons. A second type of protein, called tau, also accumulates abnormally inside neurons, damaging functions.
In the progression of AD, Aβ levels build in the brain, but the process leading to abnormally high levels is typically long. It is often years or decades before consequential symptoms of severe cognitive impairment appear. A new framework from the National Institute on Aging and Alzheimer’s Association defines the first stage of AD to be individuals with abnormal levels of Aβ who are still cognitively normal.
“Although AD pathology, and Aβ in particular, appear long before severe cognitive deficits appear,” said first author Jeremy A. Elman, PhD, assistant professor in the Department of Psychiatry at UC San Diego School of Medicine, “recent evidence suggests more subtle cognitive changes may appear earlier in the disease than commonly appreciated.”
Elman and colleagues, including senior author William S. Kremen, PhD, professor of psychiatry at UC San Diego School of Medicine, sought to determine whether poor cognitive performance, however subtle, might be a predictor that current Aβ-negative levels (accumulations below the threshold for AD diagnosis) were likely to become Aβ-positive.
“Once a person reaches the point of being Aβ-positive, it means that there is already substantial underlying pathology,” said Kremen. “It would be advantageous to identify at-risk individuals before they develop substantial amyloid burden to improve treatment efficacy and slow progression to AD dementia.”
The researchers conducted a pair of non-invasive cognitive tests on 292 participants in the Alzheimer’s Disease Neuroimaging Initiative, an ongoing study to assess whether the use of medical imaging, biological markers and clinical assessments can be combined to measure the progression of cognitive decline and early AD.
All of the participants were Aβ-negative at baseline testing and displayed no dementia; 40 participants would progress to Aβ-positivity during the study and follow-up period.
The scientists found that participants who tested with lower baseline cognition were at significantly higher risk of progressing to Aβ-positivity. That is, low test scores indicating poorer cognitive function suggested amyloid plaque levels that, while not yet considered to be problematic, were likely rising and would ultimately reach the threshold definition of AD.
“We found that subthreshold levels of baseline Aβ were predictive of future accumulation, adding to evidence that even low levels of Aβ are clinically relevant, but that cognitive performance was still significantly predictive even after controlling for this pathology,” said Elman.
The findings, wrote the researchers, suggest that low-cost, non-invasive cognitive testing is useful for identifying persons who may be at risk for developing AD, making them ideal candidates for therapeutic intervention and clinical trials.
Co-authors include: Matthew S. Panizzon, Carol E. Franz and Mark E. Sanderson-Cimino, all at UC San Diego; Daniel Gustavson, UC San Diego and Vanderbilt University; and Michael J. Lyons, Boston University.
Funding for this research came, in part, from the National Institute on Aging (grants R01-AG050595, R01-AG022381, R01-AG059329, R01-AG056410 AND K08-AG047903), The Alzheimer’s Disease Neuroimaging Initiative (NIH grant U01-AG024904) and Department of Defense ADNI (W81-XWH-12-2-0012).
Neurological Care Senior Medicine Behavioral & Mental Health Care